The Quantellect read.As of Nov 19, 2026, 7 active firms cover Collegium Pharmaceutical Inc: 6 rate it Buy or better, 1 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets are tightly clustered, $43.00 to $60.00, so the covering firms are broadly aligned. The average target of $48.71 sits 88% above the current $25.96. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 4 to 6 over recent months. On the fundamentals, the Street sees consensus EPS building from about $1.58 next quarter toward $7.08 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS7 active firms
Buy
Strong Buy00%
Buy686%
Neutral114%
Sell00%
Strong Sell00%
Based on 7 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$48.71
+87.7% upside
Average target across 7 active firms as of Nov 19, 2026 vs $25.96 current
Highest Target$60.00
Average Target$48.71
Lowest Target$43.00
Detailed analyst forecasts for COLL
Showing 1–7 of 7 named analysts shown · 7 active firms in the rating projection
As of Nov 19, 2026, 6 of 7 active firms rate COLL a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
COLL EPS & revenue forecast
EPS · NEXT QUARTER
$1.58
Range $1.25 – $1.79 · 5 analysts · -10% YoY
Next period, 5 analysts expect Collegium Pharmaceutical Inc to earn $1.58 a share (range $1.25 – $1.79), versus $1.76 a year earlier. Full-year consensus is $7.46, growing to $7.08 the year after.
REVENUE · NEXT QUARTER
$200.7M
Range $185.1M – $206.4M · 5 analysts · +4% YoY
Revenue is expected to reach $200.7M (range $185.1M – $206.4M), +3.7% year-over-year. Full-year consensus is $832.0M, rising to $847.7M next year.
Top analysts covering Collegium Pharmaceutical Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on COLL.
#1
David Amsellem
Piper Sandler · Rank #124
Neutral
$43.00+65.6% to target
Overall win rate
50%
+ Follow
#2
Serge Belanger
Needham · Rank #129
Buy
$46.00+77.2% to target
Overall win rate
46%
+ Follow
#3
Oren Livnat
HC Wainwright & Co. · Rank #217
Buy
$50.00+92.6% to target
Overall win rate
54%
+ Follow
#4
BF
Brandon Folkes
HC Wainwright & Co. · Rank #402
Buy
$60.00+131.1% to target
Overall win rate
38%
+ Follow
#5
GS
Glen Santangelo
Barclays
Buy
$48.00+84.9% to target
Coverage
—
+ Follow
COLL stock forecast FAQ
What is COLL's average 12-month price target?+
The 7 active firms with a live target average $48.71 for Collegium Pharmaceutical Inc over the next 12 months, ranging from a $60.00 high to a $43.00 low, as of Nov 19, 2026.
Is COLL stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 7 active firms as of Nov 19, 2026, 6 rate it Buy or Strong Buy, 1 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for COLL?+
The Street-high target is $60.00 (HC Wainwright & Co.), and the Street-low is $43.00 (Piper Sandler). The average of all 7 active-firm targets is $48.71.
How many active Wall Street firms cover COLL?+
7 active firms have a recognized rating on Collegium Pharmaceutical Inc as of Nov 19, 2026, and 7 active firms carry a live 12-month price target.
Who is the most accurate analyst covering COLL?+
Among analysts who currently cover COLL, David Amsellem of Piper Sandler has the strongest overall Quantellect track record (Rank #124). Their current call is Neutral with a $43.00 target.
What is Collegium Pharmaceutical Inc's projected EPS for next quarter?+
The consensus estimate is $1.58 per share (range $1.25 – $1.79) across 5 analysts. Full-year EPS is projected at $7.46, rising to $7.08 the following year.
How much revenue is Collegium Pharmaceutical Inc expected to report next quarter?+
Consensus revenue is $200.7M (range $185.1M – $206.4M). Full-year revenue is projected at $832.0M, growing to $847.7M next year.
Have analysts been upgrading or downgrading COLL lately?+
As of Nov 19, 2026, 6 of 7 active firms rate COLL a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their COLL calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.